Scienture Holdings Inc

Scienture Holdings Inc(MEDS)股票分析

$1.165

-0.053 (-4.51%)收盤時

Loading chart…
最高
1.240
開盤
1.200
成交量加權均價
1.18
成交量
114.44K
市值
18.51M
最低
1.130
成交金額
134.84K
企業價值/稅息折舊攤銷前利潤(TTM)
0.00

DataMeds AI, Inc., formerly Wellgistics Health, Inc., is a holding company. It is engaged in health information technology (IT) that focuses on the vertical integration of technology, pharmacy, pharmaceutical-adjacent and telemedicine business units. The Company conducts its business through two wholly owned subsidiaries, Wood Sage, LLC and Wellgistics LLC, and two indirect subsidiaries, Alliance Pharma Solutions, LLC and Community Specialty Pharmacy, LLC. It is focused on improving the lives of patients while delivering solutions for pharmacies, providers, pharmaceutical manufacturers, and payors. Its technology platform, DelivMeds, serves as a pharmacy hub and allows clinical services to be connected to its health pharmacy operations. This platform will allow for an end-to-end mobile application solution whereby patients can digitize their prescription journey. The solution helps to preserve patient autonomy, prescription price transparency, and provide additional concierge services.

AI 分析 of Scienture Holdings Inc (MEDS)

賣出

TRxADE Health Inc (MEDS) is not a good buy right now due to significant financial losses and poor technical indicators. The current price is $1.17, with a 5-day change of -39.32% and a year-to-date change of -66.90%. The RSI is at 9.228, indicating that the stock is extremely oversold, but this does not guarantee a rebound. The main risk is the company's negative net income, which reached -$18,363,225 in Q2 2026, reflecting ongoing financial instability.

估值指標

Scienture Holdings Inc(MEDS)目前預期本益比為 0.00,5 年平均預期本益比為 21.83。

預期本益比

嚴重低估
5 年均值 P/E
21.83
目前P/E
0.00
高估
21.83
低估
21.83

預期 EV/EBITDA

嚴重高估
5 年均值 EV/EBITDA
-0.01
目前EV/EBITDA
0.00
高估
-0.01
低估
-0.01

預期股價營收比

嚴重低估
5 年均值 P/S
1.43
目前P/S
0.00
高估
1.43
低估
1.43

事件時間軸

2026-11-05 (ET)

10:00:00

DataMeds AI Signs MOU with Florida HMO

2026-11-03 (ET)

18:30:00

DataMeds AI Terminates Letter of Intent with Datavault AI

2026-11-02 (ET)

06:30:00

DataMeds AI Subsidiary Corexa Health Signs Drug Supply Agreement

2026-10-22 (ET)

08:30:00

Datavault AI Plans to Acquire 19.9% Stake in DataMEDS

08:00:00

DataMEDS Enters into Letter of Intent with Datavault AI

資訊

MEDS 常見問題 —— 由 Alphio AI 解答

DataMeds AI, Inc., formerly Wellgistics Health, Inc., is a holding company. It is engaged in health information technology (IT) that focuses on the vertical integration of technology, pharmacy, pharmaceutical-adjacent and telemedicine business units. The Company conducts its business through two wholly owned subsidiaries, Wood Sage, LLC and Wellgistics LLC, and two indirect subsidiaries, Alliance Pharma Solutions, LLC and Community Specialty Pharmacy, LLC. It is focused on improving the lives of patients while delivering solutions for pharmacies, providers, pharmaceutical manufacturers, and payors. Its technology platform, DelivMeds, serves as a pharmacy hub and allows clinical services to be connected to its health pharmacy operations. This platform will allow for an end-to-end mobile application solution whereby patients can digitize their prescription journey. The solution helps to preserve patient autonomy, prescription price transparency, and provide additional concierge services. It operates in the Healthcare sector (WHOLESALE-DRUGS, PROPRIETARIES & DRUGGISTS' SUNDRI industry).

TRxADE Health Inc (MEDS) is not a good buy right now due to significant financial losses and poor technical indicators. The current price is $1.17, with a 5-day change of -39.32% and a year-to-date change of -66.90%. The RSI is at 9.228, indicating that the stock is extremely oversold, but this does not guarantee a rebound. The main risk is the company's negative net income, which reached -$18,363,225 in Q2 2026, reflecting ongoing financial instability.

註冊或登入後參與討論

相關文章

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易